Royal Bank of Canada’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-361
| Closed | -$27K | – | 8235 |
|
|
2022
Q2 | $27K | Sell |
361
-2,808
| -89% | -$125K | ﹤0.01% | 5983 |
|
|
2022
Q1 | $85K | Sell |
3,169
-6,327
| -67% | -$213K | ﹤0.01% | 5772 |
|
|
2021
Q4 | $453K | Buy |
9,496
+7,398
| +353% | +$331K | ﹤0.01% | 4558 |
|
|
2021
Q3 | $139K | Sell |
2,098
-14,649
| -87% | -$1.04M | ﹤0.01% | 5474 |
|
|
2021
Q2 | $1.31M | Sell |
16,747
-34,546
| -67% | -$2.55M | ﹤0.01% | 3431 |
|
|
2021
Q1 | $4.85M | Sell |
51,293
-3,001
| -6% | -$357K | ﹤0.01% | 2261 |
|
|
2020
Q4 | $6.62M | Sell |
54,294
-39
| -0.1% | -$4.27K | ﹤0.01% | 1998 |
|
|
2020
Q3 | $4.75M | Buy |
54,333
+29,844
| +122% | +$2.08M | ﹤0.01% | 2042 |
|
|
2020
Q2 | $1.58M | Buy |
24,489
+422
| +2% | +$24.3K | ﹤0.01% | 2813 |
|
|
2020
Q1 | $1.07M | Buy |
24,067
+22,290
| +1,254% | +$1.18M | ﹤0.01% | 2971 |
|
|
2019
Q4 | $111K | Buy |
+1,777
| New | +$84.6K | ﹤0.01% | 5033 |
|
|
2019
Q3 | – | Sell |
-112
| Closed | -$5K | – | 7316 |
|
|
2019
Q2 | $5K | Buy |
+112
| New | +$4K | ﹤0.01% | 6354 |
|
Royal Bank of Canada's TPTX Position: Q3 2022 in Review
Royal Bank of Canada sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 361 shares — an estimated $27K sold.
Royal Bank of Canada first reported a position in TPTX in Q2 2019 and held it in 12 quarters. The position peaked at $6.62M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- Royal Bank of Canada reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Royal Bank of Canada sold 361 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $27K.
- Royal Bank of Canada first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
- Royal Bank of Canada's Turning Point Therapeutics, Inc. Common Stock position peaked at $6.62M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on Royal Bank of Canada's 13F filing for Q3 2022, filed 14 Nov 2022.